Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors

• Our medicines

  

  • Arimidex
  • Crestor
  • Nexium
  • Seroquel
  • Symbicort
  • View all medicines

• Our responsibility

  

  • Animal research
  • Clinical trials
  • Patient safety
  • Sales and marketing
  • Pharmaceuticals in the environment
  • more information

• CEO interview

  • Video1
    David Brennan, our CEO discusses 2009 results and the outlook for the next five years.
    View part twoDownload podcast, vodcast and transcriptView financial results

• Latest news collapse

  • 04 December 2009 US FDA Approves Seroquel For The Paediatric Treatment Of Schizophrenia And Bipolar Mania

    AstraZeneca today announced that the US Food and Drug Administration (FDA) approved SEROQUEL (quetiapine fumarate) Tablets for the treatment of schizophrenia in adolescents (13-17 years of age) as monotherapy, and for the acute treatment of manic episodes associated with bipolar I disorder in children and adolescents (10-17 years of age), both as monotherapy and as an adjunct to lithium or divalproex.

  • 03 December 2009 AstraZeneca and Targacept Form Global Collaboration and Licence Agreement for Late-Stage Investigational Product TC-5214 for the Treatment of Major Depressive Disorder

    AstraZeneca and Targacept, Inc. today announced a collaboration and licence agreement for the global development and commercialisation of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently completed a phase IIb clinical trial, is a nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor (NNR) subtypes.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next